Oncology and Hematology - Prova Education

Episodes 49-64 of 113

Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
MinuteCE®
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
MinuteCE®
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
1.50 program credits
- Erica L. Mayer, MD, MPH
1.50 program credits
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Gastrointestinal Cancers
1.25 credits 10 episodes
- Sara Lonardi, MD
- Aparna R. Parikh, MD
- Alan Venook, MD
1.25 credits 10 episodes
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
MinuteCE®
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
1.25 program credits
- Sara Lonardi, MD
1.25 program credits
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
MinuteCE®
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
1.25 program credits
- Alan Venook, MD
1.25 program credits
MinuteCE®
Innovations in Oncology Learning Center: From Guidelines to Practice—Breast Cancer
1.50 credits 10 episodes
- William J. Gradishar, MD
- Erica L. Mayer, MD, MPH
- Peter Schmid, FRCP, MD, PhD
1.50 credits 10 episodes
Management of HER2-Low MBC Following First-Line Disease Progression
Management of HER2-Low MBC Following First-Line Disease Progression
MinuteCE®
Management of HER2-Low MBC Following First-Line Disease Progression
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
MinuteCE®
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
1.25 program credits
- Sara Lonardi, MD
1.25 program credits
The Evolving Treatment Landscape for MBC: Emerging Therapies
The Evolving Treatment Landscape for MBC: Emerging Therapies
MinuteCE®
The Evolving Treatment Landscape for MBC: Emerging Therapies
1.50 program credits
- William J. Gradishar, MD
1.50 program credits
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
MinuteCE®
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
1.25 program credits
- Aparna R. Parikh, MD
1.25 program credits
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
MinuteCE®
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
1.25 program credits
- Alan Venook, MD
1.25 program credits
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
MinuteCE®
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
1.25 program credits
- Wenxin Xu, MD
- Sandy Srinivas, MD
1.25 program credits
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
MinuteCE®
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
1.00 program credit
- Ritu Salani, MD, MBA
- Nicoletta Colombo, MD
1.00 program credit
Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer
Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer
MinuteCE®
Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer
0.75 program credits
- Tanya Dorff, MD
0.75 program credits
Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
MinuteCE®
Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
1.00 program credit
- Nicoletta Colombo, MD
- Susana Campos, MD, MPH
1.00 program credit
Recent Advances in ADT: New Insights in Advanced Prostate Cancer Treatment
Recent Advances in ADT: New Insights in Advanced Prostate Cancer Treatment
MinuteCE®
Recent Advances in ADT: New Insights in Advanced Prostate Cancer Treatment
0.75 program credits
- Tanya Dorff, MD
- Rana McKay, MD
0.75 program credits

4/8